LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

ctDNA-Based Liquid Biopsy Test Screens for 10 Common Cancers in Single Blood Draw

By LabMedica International staff writers
Posted on 11 May 2023
Print article
Image: LucenceINSIGHT enables early cancer detection through a single blood test (Photo courtesy of Freepix)
Image: LucenceINSIGHT enables early cancer detection through a single blood test (Photo courtesy of Freepix)

As the elderly population increases, there's an escalating crisis in cancer, with new cases being reported in the millions annually. The shortfall in screening resources and poor adoption of conventional cancer screening methods result in most patients being diagnosed at advanced stages. Detecting cancer early, when it is still highly treatable, can avert unnecessary deaths due to the disease. A pioneering multi-cancer early detection (MCED) test now offers the potential for early cancer detection by screening for the risk of up to 10 cancers in a simple blood draw.

Lucence Health (Palo Alto, CA, USA) has introduced LucenceINSIGHT, a ctDNA-based liquid biopsy test capable of screening for 10 common cancers with a single blood draw. It is important to note that 78% of global cancer deaths are attributable to cancers for which there is no routine screening recommended. Blood testing could render the screening of various cancer types more accessible and convenient for people without symptoms.

LucenceINSIGHT identifies cancer-linked changes in DNA fragments found in the blood. These fragments, also referred to as circulating tumor DNA or ctDNA, are released into the bloodstream from cancer cells. Sophisticated sequence analysis is employed by the test to predict the site of origin. Results are presented as areas of concern, which healthcare providers may choose to investigate further if needed. Utilizing Lucence's unique next-generation sequencing technology, LucenceINSIGHT screens for cancer risks with a sensitivity rate of 73% and a specificity rate of 96%.

“Our mission is early cancer detection through a single blood test, when cancer is most treatable hopefully for cure,” said Lucence CEO and Medical Director Dr. Min-Han Tan. “We strongly believe in collaboration with partners who are motivated to overcome cancer together globally.”

Related Links:
Lucence Health 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more